X
25Aug

Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion

Goodwin | | Return|
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By: Goodwin
Source Url: https://www.jdsupra.com/legalnews/johnson-johnson-announces-acquisition-18211/

Related

Biotech & Life Sciences Trends to Consider Following JPM 2020: M&A, Venture Capital and More

The annual gathering of life sciences executives and investors in San Francisco that many now call “...

Read More >

Workplace Violence: What Does OSHA Require of Employers?

Franczek recently hosted an at capacity seminar on preventing workplace violence. As a follow-up to ...

Read More >

Financial Daily Dose 2.18.2020 | Top Story: Apple Cuts Revenue Expectations and HSBC Axes Jobs as Coronavirus Infects Business Outlook

Apple announced that the coronavirus outbreak that’s brought Chinese manufacturing to a near-stands...

Read More >

[Webinar] The Dynamics of Antitrust Agency Investigations: A Second Request Update - October 14th, 12:00 pm - 1:00 pm ET

HSR Act-driven Second Request responses require an uncommon balance of understanding, expertise, and...

Read More >

No, Unions Do Not Have A Free Speech Right To Engage In Unlawful Secondary Boycott Activity, Federal Appeals Court Rules

On October 28, 2019, the Ninth Circuit, following in the footsteps of the D.C. Circuit and the Secon...

Read More >